title: Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP).
abstract: This report compiles and summarizes all recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) regarding prevention and control of Haemophilus influenzae type b (Hib) disease in the United States. As a comprehensive summary of previously published recommendations, this report does not contain any new recommendations; it is intended for use by clinicians, public health officials, vaccination providers, and immunization program personnel as a resource. ACIP recommends routine vaccination with a licensed conjugate Hib vaccine for infants aged 2 through 6 months (2 or 3 doses, depending on vaccine product) with a booster dose at age 12 through 15 months. ACIP also recommends vaccination for certain persons at increased risk for Hib disease (i.e., persons who have early component complement deficiencies, immunoglobulin deficiency, anatomic or functional asplenia, or HIV infection; recipients of hematopoietic stem cell transplant; and recipients of chemotherapy or radiation therapy for malignant neoplasms). This report summarizes current information on Hib epidemiology in the United States and describes Hib vaccines licensed for use in the United States. Guidelines for antimicrobial chemoprophylaxis of contacts of persons with Hib disease also are provided.
authors.forename: Elizabeth C
authors.initials: EC
authors.lastname: Briere
authors.forename: Lorry
authors.initials: L
authors.lastname: Rubin
authors.forename: Pedro L
authors.initials: PL
authors.lastname: Moro
authors.forename: Amanda
authors.initials: A
authors.lastname: Cohn
authors.forename: Thomas
authors.initials: T
authors.lastname: Clark
authors.forename: Nancy
authors.initials: N
authors.lastname: Messonnier
mesh_terms: D026683:Advisory Committees; D000890:Anti-Infective Agents / Q000627:therapeutic use; D016667:Bacterial Capsules; D002487:Centers for Disease Control and Prevention, U.S.; D018890:Chemoprevention / Q000592:standards; D002675:Child, Preschool; D016358:Contact Tracing; D017277:Drug Approval / Q000706:statistics & numerical data; D006192:Haemophilus Infections / Q000453:epidemiology / Q000517:prevention & control*; D018073:Haemophilus Vaccines / Q000008:administration & dosage*; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D014481:United States / Q000453:epidemiology
chemical_list: D000890:Anti-Infective Agents; D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine